SERB Pharmaceuticals
SERB Pharmaceuticals licenses Soligenix antigen to develop ricin antidote
July 14, 2022 07:01 ET | BTG Specialty Pharmaceuticals
Philadelphia, July 14, 2022 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals has signed a worldwide exclusive license to use an antigen from Soligenix [NSDQ: SNGX] to develop a novel therapeutic treatment...
Battelle Wins $102M NIAID Biodefense Research Contract
July 18, 2012 10:30 ET | Battelle
COLUMBUS, OH--(Marketwire - Jul 18, 2012) - Battelle has won a single-source award from the U.S. Department of Health and Human Services' National Institutes of Health for evaluation and testing...